Glucose transporter 1-mediated vascular translocation of nanomedicines enhances accumulation and efficacy in solid tumors

Kazumi Suzuki, Yutaka Miura, Yuki Mochida, Takuya Miyazaki, Kazuko Toh, Yasutaka Anraku, Vinicio Melo, Xueying Liu, Takehiko Ishii, Osamu Nagano, Hideyuki Saya, Horacio Cabral, Kazunori Kataoka

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Nanomedicine modification with ligands directed to receptors on tumor blood vessels has the potential for selectively enhancing nanomedicine accumulation in malignant tissues by overcoming the vascular barrier of tumors. Nevertheless, the development of broadly applicable ligand approaches capable of promoting the transvascular transport of nanomedicines in a wide spectrum of tumors has been elusive so far. By considering the indispensable and persistent glycolytic fueling of tumors, we developed glucose-installed polymeric micelles loading cisplatin (Gluc-CDDP/m) targeting the glucose transporter 1 (GLUT1), which is overexpressed in most tumors and present on vascular endothelial cells, toward improving the delivery efficiency and therapeutic efficacy. The design of the glucose ligands on Gluc-CDDP/m was engineered to control the conjugation via the carbon 6 of the glucose moieties, as well as the ligand density on the poly (ethylene glycol) (PEG) shell of the micelles. The series of micelles was then studied in vitro and in vivo against GLUT1-high human squamous cell carcinoma of the head and neck OSC-19 cells and GLUT1-low human glioblastoma-astrocytoma U87MG cells. Our results showed that precisely tuning the micelles to have glucose ligands on 25% of their PEG chains increased the efficacy against the tumors by significantly enhancing the tumor accumulation, even in GLUT1-low U87MG tumors. The enhancement of the intratumoral levels of these micelles was hindered by concomitant administration of glucose, or the GLUT1 inhibitor STF-31, confirming a GLUT1/glucose-mediated increment of the accumulation. Intravital confocal laser scanning microscopy imaging of tumor tissues further demonstrated the rapid extravasation and penetration of Gluc-CDDP/m in OSC-19 tumors compared to non-targeted CDDP/m. These findings indicate GLUT1-targeting as a promising approach for overcoming the vascular barrier and boosting the delivery of nanomedicine in tumors.

Original languageEnglish
Pages (from-to)28-41
Number of pages14
JournalJournal of Controlled Release
Volume301
DOIs
Publication statusPublished - 2019 May 10

Fingerprint

Nanomedicine
Facilitative Glucose Transport Proteins
Blood Vessels
Micelles
Neoplasms
Glucose
Ligands
Vascular Tissue Neoplasms
Ethylene Glycol
Astrocytoma
Glioblastoma
Confocal Microscopy
Cisplatin
Carbon
Endothelial Cells

Keywords

  • Cisplatin
  • EPR effect
  • Glucose
  • GLUT1
  • Polymeric micelles
  • Tumor vasculature

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Glucose transporter 1-mediated vascular translocation of nanomedicines enhances accumulation and efficacy in solid tumors. / Suzuki, Kazumi; Miura, Yutaka; Mochida, Yuki; Miyazaki, Takuya; Toh, Kazuko; Anraku, Yasutaka; Melo, Vinicio; Liu, Xueying; Ishii, Takehiko; Nagano, Osamu; Saya, Hideyuki; Cabral, Horacio; Kataoka, Kazunori.

In: Journal of Controlled Release, Vol. 301, 10.05.2019, p. 28-41.

Research output: Contribution to journalArticle

Suzuki, K, Miura, Y, Mochida, Y, Miyazaki, T, Toh, K, Anraku, Y, Melo, V, Liu, X, Ishii, T, Nagano, O, Saya, H, Cabral, H & Kataoka, K 2019, 'Glucose transporter 1-mediated vascular translocation of nanomedicines enhances accumulation and efficacy in solid tumors', Journal of Controlled Release, vol. 301, pp. 28-41. https://doi.org/10.1016/j.jconrel.2019.02.021
Suzuki, Kazumi ; Miura, Yutaka ; Mochida, Yuki ; Miyazaki, Takuya ; Toh, Kazuko ; Anraku, Yasutaka ; Melo, Vinicio ; Liu, Xueying ; Ishii, Takehiko ; Nagano, Osamu ; Saya, Hideyuki ; Cabral, Horacio ; Kataoka, Kazunori. / Glucose transporter 1-mediated vascular translocation of nanomedicines enhances accumulation and efficacy in solid tumors. In: Journal of Controlled Release. 2019 ; Vol. 301. pp. 28-41.
@article{27897021d7794ae581da26c4754758f4,
title = "Glucose transporter 1-mediated vascular translocation of nanomedicines enhances accumulation and efficacy in solid tumors",
abstract = "Nanomedicine modification with ligands directed to receptors on tumor blood vessels has the potential for selectively enhancing nanomedicine accumulation in malignant tissues by overcoming the vascular barrier of tumors. Nevertheless, the development of broadly applicable ligand approaches capable of promoting the transvascular transport of nanomedicines in a wide spectrum of tumors has been elusive so far. By considering the indispensable and persistent glycolytic fueling of tumors, we developed glucose-installed polymeric micelles loading cisplatin (Gluc-CDDP/m) targeting the glucose transporter 1 (GLUT1), which is overexpressed in most tumors and present on vascular endothelial cells, toward improving the delivery efficiency and therapeutic efficacy. The design of the glucose ligands on Gluc-CDDP/m was engineered to control the conjugation via the carbon 6 of the glucose moieties, as well as the ligand density on the poly (ethylene glycol) (PEG) shell of the micelles. The series of micelles was then studied in vitro and in vivo against GLUT1-high human squamous cell carcinoma of the head and neck OSC-19 cells and GLUT1-low human glioblastoma-astrocytoma U87MG cells. Our results showed that precisely tuning the micelles to have glucose ligands on 25{\%} of their PEG chains increased the efficacy against the tumors by significantly enhancing the tumor accumulation, even in GLUT1-low U87MG tumors. The enhancement of the intratumoral levels of these micelles was hindered by concomitant administration of glucose, or the GLUT1 inhibitor STF-31, confirming a GLUT1/glucose-mediated increment of the accumulation. Intravital confocal laser scanning microscopy imaging of tumor tissues further demonstrated the rapid extravasation and penetration of Gluc-CDDP/m in OSC-19 tumors compared to non-targeted CDDP/m. These findings indicate GLUT1-targeting as a promising approach for overcoming the vascular barrier and boosting the delivery of nanomedicine in tumors.",
keywords = "Cisplatin, EPR effect, Glucose, GLUT1, Polymeric micelles, Tumor vasculature",
author = "Kazumi Suzuki and Yutaka Miura and Yuki Mochida and Takuya Miyazaki and Kazuko Toh and Yasutaka Anraku and Vinicio Melo and Xueying Liu and Takehiko Ishii and Osamu Nagano and Hideyuki Saya and Horacio Cabral and Kazunori Kataoka",
year = "2019",
month = "5",
day = "10",
doi = "10.1016/j.jconrel.2019.02.021",
language = "English",
volume = "301",
pages = "28--41",
journal = "Journal of Controlled Release",
issn = "0168-3659",
publisher = "Elsevier",

}

TY - JOUR

T1 - Glucose transporter 1-mediated vascular translocation of nanomedicines enhances accumulation and efficacy in solid tumors

AU - Suzuki, Kazumi

AU - Miura, Yutaka

AU - Mochida, Yuki

AU - Miyazaki, Takuya

AU - Toh, Kazuko

AU - Anraku, Yasutaka

AU - Melo, Vinicio

AU - Liu, Xueying

AU - Ishii, Takehiko

AU - Nagano, Osamu

AU - Saya, Hideyuki

AU - Cabral, Horacio

AU - Kataoka, Kazunori

PY - 2019/5/10

Y1 - 2019/5/10

N2 - Nanomedicine modification with ligands directed to receptors on tumor blood vessels has the potential for selectively enhancing nanomedicine accumulation in malignant tissues by overcoming the vascular barrier of tumors. Nevertheless, the development of broadly applicable ligand approaches capable of promoting the transvascular transport of nanomedicines in a wide spectrum of tumors has been elusive so far. By considering the indispensable and persistent glycolytic fueling of tumors, we developed glucose-installed polymeric micelles loading cisplatin (Gluc-CDDP/m) targeting the glucose transporter 1 (GLUT1), which is overexpressed in most tumors and present on vascular endothelial cells, toward improving the delivery efficiency and therapeutic efficacy. The design of the glucose ligands on Gluc-CDDP/m was engineered to control the conjugation via the carbon 6 of the glucose moieties, as well as the ligand density on the poly (ethylene glycol) (PEG) shell of the micelles. The series of micelles was then studied in vitro and in vivo against GLUT1-high human squamous cell carcinoma of the head and neck OSC-19 cells and GLUT1-low human glioblastoma-astrocytoma U87MG cells. Our results showed that precisely tuning the micelles to have glucose ligands on 25% of their PEG chains increased the efficacy against the tumors by significantly enhancing the tumor accumulation, even in GLUT1-low U87MG tumors. The enhancement of the intratumoral levels of these micelles was hindered by concomitant administration of glucose, or the GLUT1 inhibitor STF-31, confirming a GLUT1/glucose-mediated increment of the accumulation. Intravital confocal laser scanning microscopy imaging of tumor tissues further demonstrated the rapid extravasation and penetration of Gluc-CDDP/m in OSC-19 tumors compared to non-targeted CDDP/m. These findings indicate GLUT1-targeting as a promising approach for overcoming the vascular barrier and boosting the delivery of nanomedicine in tumors.

AB - Nanomedicine modification with ligands directed to receptors on tumor blood vessels has the potential for selectively enhancing nanomedicine accumulation in malignant tissues by overcoming the vascular barrier of tumors. Nevertheless, the development of broadly applicable ligand approaches capable of promoting the transvascular transport of nanomedicines in a wide spectrum of tumors has been elusive so far. By considering the indispensable and persistent glycolytic fueling of tumors, we developed glucose-installed polymeric micelles loading cisplatin (Gluc-CDDP/m) targeting the glucose transporter 1 (GLUT1), which is overexpressed in most tumors and present on vascular endothelial cells, toward improving the delivery efficiency and therapeutic efficacy. The design of the glucose ligands on Gluc-CDDP/m was engineered to control the conjugation via the carbon 6 of the glucose moieties, as well as the ligand density on the poly (ethylene glycol) (PEG) shell of the micelles. The series of micelles was then studied in vitro and in vivo against GLUT1-high human squamous cell carcinoma of the head and neck OSC-19 cells and GLUT1-low human glioblastoma-astrocytoma U87MG cells. Our results showed that precisely tuning the micelles to have glucose ligands on 25% of their PEG chains increased the efficacy against the tumors by significantly enhancing the tumor accumulation, even in GLUT1-low U87MG tumors. The enhancement of the intratumoral levels of these micelles was hindered by concomitant administration of glucose, or the GLUT1 inhibitor STF-31, confirming a GLUT1/glucose-mediated increment of the accumulation. Intravital confocal laser scanning microscopy imaging of tumor tissues further demonstrated the rapid extravasation and penetration of Gluc-CDDP/m in OSC-19 tumors compared to non-targeted CDDP/m. These findings indicate GLUT1-targeting as a promising approach for overcoming the vascular barrier and boosting the delivery of nanomedicine in tumors.

KW - Cisplatin

KW - EPR effect

KW - Glucose

KW - GLUT1

KW - Polymeric micelles

KW - Tumor vasculature

UR - http://www.scopus.com/inward/record.url?scp=85062942187&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062942187&partnerID=8YFLogxK

U2 - 10.1016/j.jconrel.2019.02.021

DO - 10.1016/j.jconrel.2019.02.021

M3 - Article

C2 - 30844476

AN - SCOPUS:85062942187

VL - 301

SP - 28

EP - 41

JO - Journal of Controlled Release

JF - Journal of Controlled Release

SN - 0168-3659

ER -